Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11852056 | 0.86 | ERN1 (0.46) | TDP1ALDH1A1MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL2885741 | 0.85 | ERN1 (0.57) | TDP1ALDH1A1CYP19A1MAPTNPSR1 | |
| SCHEMBL16960614 | 0.83 | MAPT (0.49) | TDP1ALDH1A1CYP19A1MAPTNPSR1 | |
| SCHEMBL16952296 | 0.83 | MAPT (0.47) | TDP1ALDH1A1MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL358770 | 0.82 | TDP1 (0.61) | TDP1ALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL2885770 | 0.81 | PRMT1 (0.50) | TDP1ALDH1A1CYP19A1MAPTNPSR1 | |
| SCHEMBL2884140 | 0.81 | PRMT1 (0.50) | TDP1ALDH1A1CYP19A1MAPTNPSR1 | |
| SCHEMBL2884138 | 0.81 | PRMT1 (0.50) | TDP1ALDH1A1CYP19A1MAPTNPSR1 | |
| SCHEMBL22092667 | 0.80 | RAB9A (0.42) | TDP1ALDH1A1MAPTNPSR1NPC1 | |
| SCHEMBL16952252 | 0.80 | ERN1 (0.41) | TDP1ALDH1A1MAPTNPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3507275-A1 | CXCR3 RECEPTOR AGONISTS | Celgene International II Sarl (CH) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| CN-100584459-C | The application of dehydroabietylamine thiourea catalyst in high antimer both hands control synthesizing chiral compound | UNIV LANZHOU | 2010-01-27 | — | — | CN | disclosed |
| CN-101318146-A | Application of dehydroabietylamine thiourea catalyst in synthesizing chiral compound with high-antipodism both-hand control | UNIV LANZHOU (CN) | 2008-12-10 | — | — | CN | disclosed |
| EP-0833630-A4 | NOVEL BENZOPYRAN COMPOUNDS AND METHODS FOR THEIR USE | SUGEN INC (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0833630-A1 | NOVEL BENZOPYRAN COMPOUNDS AND METHODS FOR THEIR USE | Sugen, Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996040110-A1 | NOVEL BENZOPYRAN COMPOUNDS AND METHODS FOR THEIR USE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | TDP1 4401/4885ALDH1A1 1802/4885CYP19A1 1945/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | TDP1 4401/4885ALDH1A1 1802/4885CYP19A1 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.